Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Lung Cancer

Retrieve available abstracts of 464 articles:
HTML format
Text format



Single Articles


    May 2018
  1. D'SILVA A, Gardiner PA, Boyle T, Bebb DG, et al
    Associations of objectively assessed physical activity and sedentary time with health-related quality of life among lung cancer survivors: A quantile regression approach.
    Lung Cancer. 2018;119:78-84.
    PubMed     Text format     Abstract available


  2. RAEZ LE, Cardona AF, Santos ES, Catoe H, et al
    The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments.
    Lung Cancer. 2018;119:7-13.
    PubMed     Text format     Abstract available


  3. YANG SM, Chen LW, Wang HJ, Chen LR, et al
    Extraction of radiomic values from lung adenocarcinoma with near-pure subtypes in the International Association for the Study of Lung Cancer/the American Thoracic Society/the European Respiratory Society (IASLC/ATS/ERS) classification.
    Lung Cancer. 2018;119:56-63.
    PubMed     Text format     Abstract available


  4. CHRISTOPOULOS P, Schneider MA, Bozorgmehr F, Kuon J, et al
    Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance.
    Lung Cancer. 2018;119:48-55.
    PubMed     Text format     Abstract available


  5. MODING EJ, Diehn M, Wakelee HA
    Circulating tumor DNA testing in advanced non-small cell lung cancer.
    Lung Cancer. 2018;119:42-47.
    PubMed     Text format     Abstract available


  6. FUJIMOTO D, Yoshioka H, Kataoka Y, Morimoto T, et al
    Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
    Lung Cancer. 2018;119:14-20.
    PubMed     Text format     Abstract available


  7. BORGHAEI H, Yim YM, Guerin A, Pivneva I, et al
    Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
    Lung Cancer. 2018;119:112-119.
    PubMed     Text format     Abstract available


  8. BURUDPAKDEE C, Wong W, Seetasith A, Corvino FA, et al
    Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.
    Lung Cancer. 2018;119:103-111.
    PubMed     Text format     Abstract available


  9. KANG YK, Song YS, Cho S, Jheon S, et al
    Prognostic stratification model for patients with stage I non-small cell lung cancer adenocarcinoma treated with surgical resection without adjuvant therapies using metabolic features measured on F-18 FDG PET and postoperative pathologic factors.
    Lung Cancer. 2018;119:1-6.
    PubMed     Text format     Abstract available


    April 2018
  10. LIAO WY, Ho CC, Tsai TH, Chen KY, et al
    Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Lung Cancer. 2018;118:90-96.
    PubMed     Text format     Abstract available


  11. HAINSWORTH JD, Waterhouse DM, Shih KC, Boccia RV, et al
    Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).
    Lung Cancer. 2018;118:6-12.
    PubMed     Text format     Abstract available


  12. SONG Z, Cheng G, Xu C, Wang W, et al
    Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;118:57-61.
    PubMed     Text format     Abstract available


  13. LEE JW, Choi JS, Lyu J, Lee SM, et al
    Prognostic significance of (18)F-fluorodeoxyglucose uptake of bone marrow measured on positron emission tomography in patients with small cell lung cancer.
    Lung Cancer. 2018;118:41-47.
    PubMed     Text format     Abstract available


  14. BAINE MJ, Verma V, Schonewolf CA, Lin C, et al
    Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer.
    Lung Cancer. 2018;118:20-26.
    PubMed     Text format     Abstract available


  15. HELFRICH BA, Gao D, Bunn PA Jr
    Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.
    Lung Cancer. 2018;118:148-154.
    PubMed     Text format     Abstract available


  16. HUDSON A, Chan C, Woolf D, McWilliam A, et al
    Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?
    Lung Cancer. 2018;118:139-147.
    PubMed     Text format     Abstract available


  17. SAKAKURA N, Mizuno T, Kuroda H, Arimura T, et al
    The eighth TNM classification system for lung cancer: A consideration based on the degree of pleural invasion and involved neighboring structures.
    Lung Cancer. 2018;118:134-138.
    PubMed     Text format     Abstract available


  18. IMAI S, Kobayashi M, Takasaki C, Ishibashi H, et al
    High expression of P-cadherin is significantly associated with poor prognosis in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;118:13-19.
    PubMed     Text format     Abstract available


  19. COUNAGO F, Rodriguez de Dios N, Montemuino S, Jove-Teixido J, et al
    Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
    Lung Cancer. 2018;118:119-127.
    PubMed     Text format     Abstract available


  20. FILIPSKA M, Skrzypski M, Czetyrbok K, Stokowy T, et al
    MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma.
    Lung Cancer. 2018;118:111-118.
    PubMed     Text format     Abstract available


  21. LIU Y, Li Y, Ou Q, Wu X, et al
    Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Lung Cancer. 2018;118:1-5.
    PubMed     Text format     Abstract available


    March 2018
  22. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Corrigendum to "Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation" [Lung Cancer 112, (October) (2017) 81-89].
    Lung Cancer. 2018 Mar 19. pii: S0169-5002(18)30301.
    PubMed     Text format    


  23. LI J, Wang Z, Groen HJM, Zhao J, et al
    Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.
    Lung Cancer. 2018 Mar 1. pii: S0169-5002(18)30273.
    PubMed     Text format    


  24. GERBER DE, Socinski MA, Neal JW, Wakelee HA, et al
    Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
    Lung Cancer. 2018;117:44-49.
    PubMed     Text format     Abstract available


  25. SPIGEL DR, Hainsworth JD, Shipley DL, Mekhail TM, et al
    Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.
    Lung Cancer. 2018;117:38-43.
    PubMed     Text format     Abstract available


  26. SCULIER JP, Lafitte JJ, Berghmans T, Meert AP, et al
    A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.
    Lung Cancer. 2018;117:32-37.
    PubMed     Text format     Abstract available


  27. ZHANG B, Xu J, Zhang X, Gu P, et al
    Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
    Lung Cancer. 2018;117:27-31.
    PubMed     Text format     Abstract available


  28. YANG W, Qian F, Teng J, Wang H, et al
    Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening.
    Lung Cancer. 2018;117:20-26.
    PubMed     Text format     Abstract available


  29. OKAMOTO I, Morita S, Tashiro N, Imamura F, et al
    Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.
    Lung Cancer. 2018;117:14-19.
    PubMed     Text format     Abstract available


  30. ARIYASU R, Nishikawa S, Uchibori K, Oh-Hara T, et al
    High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.
    Lung Cancer. 2018;117:1-6.
    PubMed     Text format     Abstract available


    February 2018
  31. ODA K, Kato K, Nakamura M, Jotatsu T, et al
    Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab.
    Lung Cancer. 2018 Feb 21. pii: S0169-5002(18)30269.
    PubMed     Text format    


  32. BARUA S, Fang P, Sharma A, Fujimoto J, et al
    Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer.
    Lung Cancer. 2018 Feb 3. pii: S0169-5002(18)30236.
    PubMed     Text format     Abstract available


  33. VANDERLAAN PA, Rangachari D, Majid A, Parikh MS, et al
    Tumor biomarker testing in non-small-cell lung cancer: A decade of change.
    Lung Cancer. 2018;116:90-95.
    PubMed     Text format     Abstract available


  34. CHENG CC, Chou KF, Wu CW, Su NW, et al
    EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres as a therapeutic target against EGFR-positive non-small cell lung cancer.
    Lung Cancer. 2018;116:80-89.
    PubMed     Text format     Abstract available


  35. ARAN V, Masson Domingues P, Carvalho de Macedo F, Moreira de Sousa CA, et al
    A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients.
    Lung Cancer. 2018;116:7-14.
    PubMed     Text format     Abstract available


  36. GAUVAIN C, Vauleon E, Chouaid C, Lerhun E, et al
    Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.
    Lung Cancer. 2018;116:62-66.
    PubMed     Text format     Abstract available


  37. DRIESSEN EJM, Schulkes KJG, Dingemans AC, van Loon JGM, et al
    Patterns of treatment and survival among older patients with stage III non-small cell lung cancer.
    Lung Cancer. 2018;116:55-61.
    PubMed     Text format     Abstract available


  38. CUI S, Cheng Z, Qin W, Jiang L, et al
    Exosomes as a liquid biopsy for lung cancer.
    Lung Cancer. 2018;116:46-54.
    PubMed     Text format     Abstract available


  39. PARK KS, Moon YW, Raffeld M, Lee DH, et al
    High cripto-1 and low miR-205 expression levels as prognostic markers in early stage non-small cell lung cancer.
    Lung Cancer. 2018;116:38-45.
    PubMed     Text format     Abstract available


  40. ARNEY J, Helm A, Crook T, Braun UK, et al
    Utilization of genomic testing in advanced non-small cell lung cancer among oncologists in the Veterans Health Administration.
    Lung Cancer. 2018;116:25-29.
    PubMed     Text format     Abstract available


  41. MCLEER-FLORIN A, Duruisseaux M, Pinsolle J, Dubourd S, et al
    ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
    Lung Cancer. 2018;116:15-24.
    PubMed     Text format     Abstract available


  42. REMON J, Pardo N, Martinez-Marti A, Cedres S, et al
    Corrigendum to "Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches" [Lung Cancer 106 (2017) 70-75].
    Lung Cancer. 2018 Feb 1. pii: S0169-5002(17)30564.
    PubMed     Text format    


    January 2018
  43. GOROSPE L, Arrieta P, Ajuria-Illarramendi O, Barbolla-Diaz I, et al
    Pulmonary aspergilloma mimicking synchronous lung cancer on PET/CT in a patient with head and neck cancer.
    Lung Cancer. 2018 Jan 17. pii: S0169-5002(18)30018.
    PubMed     Text format    


  44. KHAN SA, Pruitt SL, Xuan L, Makris U, et al
    How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.
    Lung Cancer. 2018;115:97-102.
    PubMed     Text format     Abstract available


  45. LEE J, Kim HK, Park BJ, Cho JH, et al
    Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer.
    Lung Cancer. 2018;115:89-96.
    PubMed     Text format     Abstract available


  46. TAN PS, Aguiar P Jr, Haaland B, Lopes G, et al
    Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
    Lung Cancer. 2018;115:84-88.
    PubMed     Text format     Abstract available


  47. YANG CJ, Gu L, Shah SA, Yerokun BA, et al
    Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis.
    Lung Cancer. 2018;115:75-83.
    PubMed     Text format     Abstract available


  48. SATO K, Akamatsu H, Murakami E, Sasaki S, et al
    Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Lung Cancer. 2018;115:71-74.
    PubMed     Text format     Abstract available


  49. HUANG HC, Su WJ, Chiang CL, Feng JY, et al
    The predictive value of the interferon-gamma release assay for chemotherapy responses in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2018;115:64-70.
    PubMed     Text format     Abstract available


  50. TOURNOY KG, Thomeer M, Germonpre P, Derijcke S, et al
    Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.
    Lung Cancer. 2018;115:49-55.
    PubMed     Text format     Abstract available


  51. THAWANI R, McLane M, Beig N, Ghose S, et al
    Radiomics and radiogenomics in lung cancer: A review for the clinician.
    Lung Cancer. 2018;115:34-41.
    PubMed     Text format     Abstract available


  52. ISAKA M, Kojima H, Takahashi S, Omae K, et al
    Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: Implications for adjuvant therapy.
    Lung Cancer. 2018;115:28-33.
    PubMed     Text format     Abstract available


  53. EVISON M, Edwards T, Balata H, Tempowski A, et al
    Prevalence of nodal metastases in lymph node stations 8 & 9 in a large UK lung cancer surgical centre without routine pre-operative EUS nodal staging.
    Lung Cancer. 2018;115:127-130.
    PubMed     Text format     Abstract available


  54. SOO RA, Lim SM, Syn NL, Teng R, et al
    Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    Lung Cancer. 2018;115:12-20.
    PubMed     Text format     Abstract available


  55. TANAKA K, Isse K, Fujihira T, Takenoyama M, et al
    Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
    Lung Cancer. 2018;115:116-120.
    PubMed     Text format     Abstract available


  56. LIU X, Jiang T, Li W, Li X, et al
    Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer.
    Lung Cancer. 2018;115:109-115.
    PubMed     Text format     Abstract available


  57. NINOMIYA T, Nogami N, Kozuki T, Harada D, et al
    A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
    Lung Cancer. 2018;115:103-108.
    PubMed     Text format     Abstract available


    December 2017
  58. LIU E, Guha A, Jia K, Ayers AM, et al
    Corrigendum to "Cardiogenic shock in a patient being treated with Atezolizumab for metastatic non-small cell lung cancer" [Lung Cancer, 114, (December) (2017) 106-107].
    Lung Cancer. 2017 Dec 29. pii: S0169-5002(17)30621.
    PubMed     Text format    


  59. VYFHUIS MAL, Bhooshan N, Molitoris J, Bentzen SM, et al
    Corrigendum to "Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer" [Lung Cancer 114, (December 2017) 44-49].
    Lung Cancer. 2017 Dec 27. pii: S0169-5002(17)30618.
    PubMed     Text format    


  60. GROSSI F, Genova C, Rijavec E, Barletta G, et al
    Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.
    Lung Cancer. 2017 Dec 13. pii: S0169-5002(17)30614.
    PubMed     Text format     Abstract available


  61. TU HY, Ke EE, Yang JJ, Sun YL, et al
    A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
    Lung Cancer. 2017;114:96-102.
    PubMed     Text format     Abstract available


  62. TIAN HX, Zhang XC, Yang JJ, Guo WB, et al
    Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients.
    Lung Cancer. 2017;114:90-95.
    PubMed     Text format     Abstract available


  63. SHEN J, Ye Y, Chang DW, Huang M, et al
    Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
    Lung Cancer. 2017;114:70-78.
    PubMed     Text format     Abstract available


  64. CHALMERS A, Jensen L, Akerley W
    Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report.
    Lung Cancer. 2017;114:68-69.
    PubMed     Text format     Abstract available


  65. ZHU Y, Li T, Chen G, Yan G, et al
    Identification of a serum microRNA expression signature for detection of lung cancer, involving miR-23b, miR-221, miR-148b and miR-423-3p.
    Lung Cancer. 2017;114:6-11.
    PubMed     Text format     Abstract available


  66. KEUSTERS WR, de Weger VA, Hovels A, Schellens JHM, et al
    Changing costs of metastatic non small cell lung cancer in the Netherlands.
    Lung Cancer. 2017;114:56-61.
    PubMed     Text format     Abstract available


  67. VYFHUIS MAL, Bhooshan N, Molitoris J, Bentzen SM, et al
    Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer.
    Lung Cancer. 2017;114:44-49.
    PubMed     Text format     Abstract available


  68. WANG X, Leader JK, Wang R, Wilson D, et al
    Vasculature surrounding a nodule: A novel lung cancer biomarker.
    Lung Cancer. 2017;114:38-43.
    PubMed     Text format     Abstract available


  69. ZANON M, Pacini GS, de Souza VVS, Marchiori E, et al
    Early detection of lung cancer using ultra-low-dose computed tomography in coronary CT angiography scans among patients with suspected coronary heart disease.
    Lung Cancer. 2017;114:1-5.
    PubMed     Text format     Abstract available


  70. HAN L, Lee CK, Pang H, Chan HT, et al
    Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status.
    Lung Cancer. 2017;114:79-89.
    PubMed     Text format     Abstract available


  71. YAMAUCHI Y, Safi S, Muley T, Warth A, et al
    C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients.
    Lung Cancer. 2017;114:62-67.
    PubMed     Text format     Abstract available


  72. KUIJVENHOVEN JC, Crombag L, Breen DP, van den Berk I, et al
    Esophageal ultrasound (EUS) assessment of T4 status in NSCLC patients.
    Lung Cancer. 2017;114:50-55.
    PubMed     Text format     Abstract available


  73. WANG L, Guo Q, Yu W, Qiao L, et al
    Quantification of plasma EGFR mutations in patients with lung cancers: Comparison of the performance of ARMS-Plus and droplet digital PCR.
    Lung Cancer. 2017;114:31-37.
    PubMed     Text format     Abstract available


  74. MATSUMURA Y, Suzuki H, Ohira T, Shiono S, et al
    Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
    Lung Cancer. 2017;114:23-30.
    PubMed     Text format     Abstract available


  75. FOY V, Schenk MW, Baker K, Gomes F, et al
    Targeting DNA damage in SCLC.
    Lung Cancer. 2017;114:12-22.
    PubMed     Text format     Abstract available


    November 2017
  76. DUDNIK E, Moskovitz M, Daher S, Shamai S, et al
    Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
    Lung Cancer. 2017 Nov 23. pii: S0169-5002(17)30582.
    PubMed     Text format     Abstract available


  77. SCHOUTEN RD, Muller M, de Gooijer CJ, Baas P, et al
    Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute.
    Lung Cancer. 2017 Nov 17. pii: S0169-5002(17)30569.
    PubMed     Text format    


  78. GOROSPE L, Garcia-Latorre R, Ajuria-Illarramendi O, Arrieta P, et al
    Lipoid pneumonia mimicking multifocal lung cancer in a patient with a remote laryngectomy and a recently diagnosed lung cancer: PET/CT findings.
    Lung Cancer. 2017 Nov 7. pii: S0169-5002(17)30560.
    PubMed     Text format    


  79. GOROSPE L, Sanchez-Monforte JC, Cabanas-Montero J, Arrieta P, et al
    Incidental retroperitoneal malignant solitary fibrous tumor detected at lung cancer screening with low-dose thoracic CT.
    Lung Cancer. 2017 Nov 6. pii: S0169-5002(17)30561.
    PubMed     Text format    


  80. AHMED Z, Grover P, Kennedy KF, Masood A, et al
    Predictors for chemotherapy in early stage small cell lung carcinoma (SCLC): A National Cancer Database (NCDB) analysis.
    Lung Cancer. 2017;113:85-87.
    PubMed     Text format    


  81. SPIGEL DR, Rubin MS, Gian VG, Shipley DL, et al
    Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
    Lung Cancer. 2017;113:79-84.
    PubMed     Text format     Abstract available


  82. KAWANO Y, Iwama E, Tsuchihashi K, Shibahara D, et al
    CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.
    Lung Cancer. 2017;113:72-78.
    PubMed     Text format     Abstract available


  83. KATO T, Jin CS, Ujiie H, Lee D, et al
    Nanoparticle targeted folate receptor 1-enhanced photodynamic therapy for lung cancer.
    Lung Cancer. 2017;113:59-68.
    PubMed     Text format     Abstract available


  84. HORN L, Gettinger S, Camidge DR, Smit EF, et al
    Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
    Lung Cancer. 2017;113:51-58.
    PubMed     Text format     Abstract available


  85. HEUVELMANS MA, Walter JE, Peters RB, Bock GH, et al
    Relationship between nodule count and lung cancer probability in baseline CT lung cancer screening: The NELSON study.
    Lung Cancer. 2017;113:45-50.
    PubMed     Text format     Abstract available


  86. HOCHMAIR MJ, Schwab S, Burghuber OC, Krenbek D, et al
    Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy.
    Lung Cancer. 2017;113:4-6.
    PubMed     Text format     Abstract available


  87. CORRALES-RODRIGUEZ L, Arrieta O, Mas L, Baez-Saldana R, et al
    An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP).
    Lung Cancer. 2017;113:30-36.
    PubMed     Text format     Abstract available


  88. LIU C, Cui H, Gu D, Zhang M, et al
    Genetic polymorphisms and lung cancer risk: Evidence from meta-analyses and genome-wide association studies.
    Lung Cancer. 2017;113:18-29.
    PubMed     Text format     Abstract available


  89. BOUAZZA YB, Chiairi I, El Kharbouchi O, De Backer L, et al
    Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review.
    Lung Cancer. 2017;113:140-151.
    PubMed     Text format     Abstract available


  90. SANTONI-RUGIU E, Grauslund M, Melchior LC, Costa JC, et al
    Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Lung Cancer. 2017;113:14-17.
    PubMed     Text format     Abstract available


  91. ICHIKAWA T, Saruwatari K, Mimaki S, Sugano M, et al
    Immunohistochemical and genetic characteristics of lung cancer mimicking organizing pneumonia.
    Lung Cancer. 2017;113:134-139.
    PubMed     Text format     Abstract available


  92. SCHMIDT LH, Stucke-Ring J, Brand C, Schliemann C, et al
    CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
    Lung Cancer. 2017;113:121-127.
    PubMed     Text format     Abstract available


  93. TALBOT T, Dangoor A, Shah R, Naik J, et al
    The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study.
    Lung Cancer. 2017;113:115-120.
    PubMed     Text format     Abstract available


  94. LEE CK, Kim S, Lee JS, Lee JE, et al
    Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lung Cancer. 2017;113:106-114.
    PubMed     Text format     Abstract available


  95. HASSAN A, Latif MT, Soo CI, Faisal AH, et al
    Short communication: Diagnosis of lung cancer increases during the annual southeast Asian haze periods.
    Lung Cancer. 2017;113:1-3.
    PubMed     Text format     Abstract available


    October 2017
  96. SAWA K, Koh Y, Kawaguchi T, Kambayashi S, et al
    PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort.
    Lung Cancer. 2017;112:96-101.
    PubMed     Text format     Abstract available


  97. SCHVARTSMAN G, Peng SA, Bis G, Lee JJ, et al
    Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Lung Cancer. 2017;112:90-95.
    PubMed     Text format     Abstract available


  98. HSIEH FS, Hung MH, Wang CY, Chen YL, et al
    Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation.
    Lung Cancer. 2017;112:81-89.
    PubMed     Text format     Abstract available


  99. HE Y, Rozeboom L, Rivard CJ, Ellison K, et al
    MHC class II expression in lung cancer.
    Lung Cancer. 2017;112:75-80.
    PubMed     Text format     Abstract available


  100. ROS-MAZURCZYK M, Jelonek K, Marczyk M, Binczyk F, et al
    Serum lipid profile discriminates patients with early lung cancer from healthy controls.
    Lung Cancer. 2017;112:69-74.
    PubMed     Text format     Abstract available


  101. FACCHINETTI F, Bluthgen MV, Tergemina-Clain G, Faivre L, et al
    LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.
    Lung Cancer. 2017;112:62-68.
    PubMed     Text format     Abstract available


  102. TOMIZAWA K, Shimizu S, Ohara S, Fujino T, et al
    Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer.
    Lung Cancer. 2017;112:57-61.
    PubMed     Text format     Abstract available


  103. LEFRESNE S, Olson R, Cashman R, Kostuik P, et al
    Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinic.
    Lung Cancer. 2017;112:35-40.
    PubMed     Text format     Abstract available


  104. NISHIE K, Yamamoto S, Nagata C, Koizumi T, et al
    Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.
    Lung Cancer. 2017;112:25-34.
    PubMed     Text format     Abstract available


  105. KUYAMA S, Ochi N, Bessho A, Hotta K, et al
    A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
    Lung Cancer. 2017;112:188-194.
    PubMed     Text format     Abstract available


  106. RECK M, Paz-Ares L, Bidoli P, Cappuzzo F, et al
    Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
    Lung Cancer. 2017;112:181-187.
    PubMed     Text format     Abstract available


  107. QIN N, Wang C, Zhu M, Lu Q, et al
    Fine-mapping the MHC region in Asian populations identified novel variants modifying susceptibility to lung cancer.
    Lung Cancer. 2017;112:169-175.
    PubMed     Text format     Abstract available


  108. LARA JD, Brunson A, Riess JW, Kelly K, et al
    Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.
    Lung Cancer. 2017;112:165-168.
    PubMed     Text format     Abstract available


  109. VINOD SK, Chandra A, Berthelsen A, Descallar J, et al
    Does timeliness of care in Non-Small Cell Lung Cancer impact on survival?
    Lung Cancer. 2017;112:16-24.
    PubMed     Text format     Abstract available


  110. JACOBSEN MM, Silverstein SC, Quinn M, Waterston LB, et al
    Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review.
    Lung Cancer. 2017;112:156-164.
    PubMed     Text format     Abstract available


  111. EL ZOGHBI M, Salameh P, Stucker I, Paris C, et al
    Phenotypes of lung cancer and statistical interactions between tobacco smoking and occupational exposure to asbestos and crystalline silica from a large case-only study: The CaProMat study.
    Lung Cancer. 2017;112:140-155.
    PubMed     Text format     Abstract available


  112. KWINT M, Walraven I, Burgers S, Hartemink K, et al
    Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases.
    Lung Cancer. 2017;112:134-139.
    PubMed     Text format     Abstract available


  113. PAZ-ARES LG, Perol M, Ciuleanu TE, Kowalyszyn RD, et al
    Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
    Lung Cancer. 2017;112:126-133.
    PubMed     Text format     Abstract available


  114. AGGARWAL C, Wang X, Ranganathan A, Torigian D, et al
    Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.
    Lung Cancer. 2017;112:118-125.
    PubMed     Text format     Abstract available


  115. SNOECKX A, Dendooven A, Carp L, Desbuquoit D, et al
    Wolf in Sheep's Clothing: Primary Lung Cancer Mimicking Benign Entities.
    Lung Cancer. 2017;112:109-117.
    PubMed     Text format     Abstract available


  116. MEZQUITA L, Charrier M, Faivre L, Dupraz L, et al
    Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.
    Lung Cancer. 2017;112:10-15.
    PubMed     Text format     Abstract available


    September 2017
  117. ROUSSEAU-GAZANIOL C, Fraboulet S, Couderc LJ, Kreis H, et al
    Lung cancer in renal transplant recipients: A case-control study.
    Lung Cancer. 2017;111:96-100.
    PubMed     Text format     Abstract available


  118. MIURA K, Hamanaka K, Koizumi T, Kitaguchi Y, et al
    Clinical significance of preoperative serum albumin level for prognosis in surgically resected patients with non-small cell lung cancer: Comparative study of normal lung, emphysema, and pulmonary fibrosis.
    Lung Cancer. 2017;111:88-95.
    PubMed     Text format     Abstract available


  119. LIM SM, Chang H, Cha YJ, Liang S, et al
    Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lung Cancer. 2017;111:79-83.
    PubMed     Text format     Abstract available


  120. MOON SM, Lee DG, Hwang NY, Ahn S, et al
    Ipsilateral pleural recurrence after diagnostic transthoracic needle biopsy in pathological stage I lung cancer patients who underwent curative resection.
    Lung Cancer. 2017;111:69-74.
    PubMed     Text format     Abstract available


  121. TOKACA N, Wotherspoon A, Nicholson AG, Fotiadis N, et al
    Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer.
    Lung Cancer. 2017;111:65-68.
    PubMed     Text format     Abstract available


  122. CAPELAN M, Roda D, Geuna E, Rihawi K, et al
    Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
    Lung Cancer. 2017;111:6-11.
    PubMed     Text format     Abstract available


  123. CALIFANO R, Greystoke A, Lal R, Thompson J, et al
    Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Lung Cancer. 2017;111:51-58.
    PubMed     Text format     Abstract available


  124. SHEN L, Niu X, Jian H, Xu Y, et al
    Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2017;111:43-50.
    PubMed     Text format     Abstract available


  125. MORIKAWA N, Inoue A, Sugawara S, Maemondo M, et al
    Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naive extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
    Lung Cancer. 2017;111:38-42.
    PubMed     Text format     Abstract available


  126. GOBBINI E, Galetta D, Tiseo M, Graziano P, et al
    Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.
    Lung Cancer. 2017;111:30-37.
    PubMed     Text format     Abstract available


  127. LABBE C, Cabanero M, Korpanty GJ, Tomasini P, et al
    Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
    Lung Cancer. 2017;111:23-29.
    PubMed     Text format     Abstract available


  128. HATA A, Katakami N, Nanjo S, Okuda C, et al
    Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2017;111:182-189.
    PubMed     Text format     Abstract available


  129. DIEM S, Schmid S, Krapf M, Flatz L, et al
    Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Lung Cancer. 2017;111:176-181.
    PubMed     Text format     Abstract available


  130. SCULIER C, Bentea G, Ruelle L, Grigoriu B, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions.
    Lung Cancer. 2017;111:164-175.
    PubMed     Text format     Abstract available


  131. RUELLE L, Bentea G, Sideris S, El Koulali M, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles.
    Lung Cancer. 2017;111:150-163.
    PubMed     Text format     Abstract available


  132. WOHLKOENIG C, Leithner K, Olschewski A, Olschewski H, et al
    TR3 is involved in hypoxia-induced apoptosis resistance in lung cancer cells downstream of HIF-1alpha.
    Lung Cancer. 2017;111:15-22.
    PubMed     Text format     Abstract available


  133. YOUSAF-KHAN AU, van der Aalst CM, Aerts JGJV, den Bakker MA, et al
    Uniform and blinded cause of death verification of the NELSON lung cancer screening participants.
    Lung Cancer. 2017;111:131-134.
    PubMed     Text format     Abstract available


  134. GAGLIASSO M, Migliaretti G, Ardissone F
    Assessing the prognostic impact of the International Association for the Study of Lung Cancer proposed definitions of complete, uncertain, and incomplete resection in non-small cell lung cancer surgery.
    Lung Cancer. 2017;111:124-130.
    PubMed     Text format     Abstract available


  135. TAGHIZADEH N, Taylor KL, MacEachern P, Koetzler R, et al
    Tobacco use and motivation to stop smoking among long-term smokers who are ineligible for lung cancer screening.
    Lung Cancer. 2017;111:101-107.
    PubMed     Text format     Abstract available


  136. FUJIMOTO D, Morimoto T, Ito J, Sato Y, et al
    A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
    Lung Cancer. 2017;111:1-5.
    PubMed     Text format     Abstract available


    August 2017
  137. VON VERSCHUER U, Schnell R, Tessen HW, Eggert J, et al
    Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study.
    Lung Cancer. 2017 Aug 22. pii: S0169-5002(17)30419.
    PubMed     Text format     Abstract available


  138. CHENG YW, Chiou HL, Chen JT, Chou MC, et al
    Corrigendum to: 'Gender difference in human papillomarvirus infection for non-small cell lung cancer in Taiwan' [Lung Cancer 46 (November(2)) (2004) 165-170].
    Lung Cancer. 2017 Aug 18. pii: S0169-5002(17)30486.
    PubMed     Text format    


  139. LIAO BC, Lin CC, Lee JH, Yang JC, et al
    Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
    Lung Cancer. 2017;110:7-13.
    PubMed     Text format     Abstract available


  140. KIM EY, Kim A, Kim SK, Chang YS, et al
    MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
    Lung Cancer. 2017;110:63-67.
    PubMed     Text format     Abstract available


  141. KIM SH, Hyun JW, Kim HJ, Gwak HS, et al
    De novo cystic brain lesions mimicking neurocysticercosis in ALK-positive lung cancer.
    Lung Cancer. 2017;110:53-55.
    PubMed     Text format     Abstract available


  142. TAO MH, Dai Q, Chen S, Freudenheim JL, et al
    Calcium plus vitamin D supplementation and lung cancer incidence among postmenopausal women in the Women's Health Initiative.
    Lung Cancer. 2017;110:42-47.
    PubMed     Text format     Abstract available


  143. KOBAYASHI-WATANABE N, Sato A, Watanabe T, Abe T, et al
    Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer.
    Lung Cancer. 2017;110:35-41.
    PubMed     Text format     Abstract available


  144. SANDS J, Li Q, Hornberger J
    Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
    Lung Cancer. 2017;110:19-25.
    PubMed     Text format     Abstract available


  145. DICKHOFF C, Dahele M, Smit EF, Paul MA, et al
    Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: Results from the Netherlands Cancer Registry.
    Lung Cancer. 2017;110:14-18.
    PubMed     Text format     Abstract available


    July 2017
  146. LIU E, Guha A, Bertino E, Franco V, et al
    Cardiogenic shock in a patient being treated with atezolizumab for metastatic non-small cell lung cancer.
    Lung Cancer. 2017 Jul 29. pii: S0169-5002(17)30416.
    PubMed     Text format    


  147. SCHONEWOLF CA, Verma V, Post CM, Berman AT, et al
    Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
    Lung Cancer. 2017 Jul 14. pii: S0169-5002(17)30384.
    PubMed     Text format     Abstract available


  148. TAMURA T, Takagi Y, Okubo H, Yamaguchi S, et al
    Plasma concentration of osimertinib in a non-small cell lung cancer patient with chronic renal failure undergoing hemodialysis.
    Lung Cancer. 2017 Jul 8. pii: S0169-5002(17)30386.
    PubMed     Text format    


  149. YOSHIDA T, Kuroda H, Oya Y, Shimizu J, et al
    Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
    Lung Cancer. 2017;109:89-91.
    PubMed     Text format     Abstract available


  150. WAKEAM E, Acuna SA, Leighl NB, Giuliani ME, et al
    Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival.
    Lung Cancer. 2017;109:78-88.
    PubMed     Text format     Abstract available


  151. LOPEZ-PASTORINI A, Riedel R, Koryllos A, Beckers F, et al
    The impact of preoperative elevated serum C-reactive protein on postoperative morbidity and mortality after anatomic resection for lung cancer.
    Lung Cancer. 2017;109:68-73.
    PubMed     Text format     Abstract available


  152. ERIGUCHI T, Takeda A, Sanuki N, Tsurugai Y, et al
    Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer.
    Lung Cancer. 2017;109:62-67.
    PubMed     Text format     Abstract available


  153. FUJISHITA T, Okamoto T, Akamine T, Takamori S, et al
    Association of MTH1 expression with the tumor malignant potential and poor prognosis in patients with resected lung cancer.
    Lung Cancer. 2017;109:52-57.
    PubMed     Text format     Abstract available


  154. GAO SJ, Kim AW, Puchalski JT, Bramley K, et al
    Indications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT.
    Lung Cancer. 2017;109:36-41.
    PubMed     Text format     Abstract available


  155. ZIEMKE M, Patil T, Nolan K, Tippimanchai D, et al
    Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
    Lung Cancer. 2017;109:28-35.
    PubMed     Text format     Abstract available


  156. O'KANE GM, Bradbury PA, Feld R, Leighl NB, et al
    Uncommon EGFR mutations in advanced non-small cell lung cancer.
    Lung Cancer. 2017;109:137-144.
    PubMed     Text format     Abstract available


  157. WAKEAM E, Varghese TK Jr, Leighl NB, Giuliani M, et al
    Trends, practice patterns and underuse of surgery in the treatment of early stage small cell lung cancer.
    Lung Cancer. 2017;109:117-123.
    PubMed     Text format     Abstract available


  158. SUDA K, Rozeboom L, Rivard CJ, Yu H, et al
    Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
    Lung Cancer. 2017;109:1-8.
    PubMed     Text format     Abstract available


  159. DURUISSEAUX M, Antoine M, Rabbe N, Rodenas A, et al
    Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.
    Lung Cancer. 2017;109:92-100.
    PubMed     Text format     Abstract available


  160. DEARDEN S, Brown H, Jenkins S, Thress KS, et al
    EGFR T790M mutation testing within the osimertinib AURA Phase I study.
    Lung Cancer. 2017;109:9-13.
    PubMed     Text format     Abstract available


  161. RASKIN J, Masrori P, Cant A, Snoeckx A, et al
    Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody.
    Lung Cancer. 2017;109:74-77.
    PubMed     Text format     Abstract available


  162. ITO J, Fujimoto D, Nakamura A, Nagano T, et al
    Aprepitant for refractory nivolumab-induced pruritus.
    Lung Cancer. 2017;109:58-61.
    PubMed     Text format     Abstract available


  163. YOTSUKURA M, Yasuda H, Shigenobu T, Kaseda K, et al
    Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.
    Lung Cancer. 2017;109:45-51.
    PubMed     Text format     Abstract available


  164. UENAMI T, Hosono Y, Ishijima M, Kanazu M, et al
    Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
    Lung Cancer. 2017;109:42-44.
    PubMed     Text format     Abstract available


  165. ZHANG L, Li S, Choi YL, Lee J, et al
    Systematic identification of cancer-related long noncoding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-Seq.
    Lung Cancer. 2017;109:21-27.
    PubMed     Text format     Abstract available


  166. BOLAND JM, Wampfler JA, Yang P, Yi ES, et al
    Growth pattern-based grading of pulmonary adenocarcinoma-Analysis of 534 cases with comparison between observers and survival analysis.
    Lung Cancer. 2017;109:14-20.
    PubMed     Text format     Abstract available


  167. HERRERA-MARTINEZ AD, Gahete MD, Sanchez-Sanchez R, Salas RO, et al
    The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features.
    Lung Cancer. 2017;109:128-136.
    PubMed     Text format     Abstract available


  168. ZHU YJ, Zhang HB, Liu YH, Zhang FL, et al
    Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients.
    Lung Cancer. 2017;109:124-127.
    PubMed     Text format     Abstract available


  169. ZHANG L, Li J, Hu J, Li D, et al
    Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines.
    Lung Cancer. 2017;109:109-116.
    PubMed     Text format     Abstract available


  170. GADGEEL S, Goss G, Soria JC, Felip E, et al
    Evaluation of the VeriStrat((R)) serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.
    Lung Cancer. 2017;109:101-108.
    PubMed     Text format     Abstract available


    June 2017
  171. GOROSPE L, Rioja-Martin ME, Santos-Carreno AL, Pacios-Blanco RE, et al
    Supraclavicular schwannoma mimicking a lymphadenopathy in a lung cancer patient: PET/CT findings.
    Lung Cancer. 2017 Jun 8. pii: S0169-5002(17)30354.
    PubMed     Text format    


  172. ZHAO J, Guerrero A, Kelnar K, Peltier HJ, et al
    Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.
    Lung Cancer. 2017;108:96-102.
    PubMed     Text format     Abstract available


  173. GREENBERG V, Lazarev I, Frank Y, Dudnik J, et al
    Semi-automatic volumetric measurement of response to chemotherapy in lung cancer patients: How wrong are we using RECIST?
    Lung Cancer. 2017;108:90-95.
    PubMed     Text format     Abstract available


  174. IMPERATORI A, Sahnane N, Rotolo N, Franzi F, et al
    LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
    Lung Cancer. 2017;108:83-89.
    PubMed     Text format     Abstract available


  175. HIDAKA N, Iwama E, Kubo N, Harada T, et al
    Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
    Lung Cancer. 2017;108:75-82.
    PubMed     Text format     Abstract available


  176. GION M, Remon J, Caramella C, Soria JC, et al
    Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.
    Lung Cancer. 2017;108:72-74.
    PubMed     Text format     Abstract available


  177. NIHO S, Ohe Y, Ohmatsu H, Umemura S, et al
    Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
    Lung Cancer. 2017;108:66-71.
    PubMed     Text format     Abstract available


  178. MCEVOY SH, Halpenny DF, Viteri-Jusue A, Hayes SA, et al
    Investigation of patterns of nodal metastases in BRAF mutant lung cancer.
    Lung Cancer. 2017;108:62-65.
    PubMed     Text format     Abstract available


  179. YU XQ, Luo Q, Kahn C, Grogan P, et al
    Contrasting temporal trends in lung cancer incidence by socioeconomic status among women in New South Wales, Australia, 1985-2009.
    Lung Cancer. 2017;108:55-61.
    PubMed     Text format     Abstract available


  180. CROMBAG LMMJ, Szlubowski A, Stigt JA, Schuurbiers O, et al
    EUS-B-FNA vs conventional EUS-FNA for left adrenal gland analysis in lung cancer patients.
    Lung Cancer. 2017;108:38-44.
    PubMed     Text format     Abstract available


  181. SEKINE I, Harada H, Yamamoto N, Wakabayashi M, et al
    Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
    Lung Cancer. 2017;108:232-237.
    PubMed     Text format     Abstract available


  182. KOSHY M, Malik R, Spiotto M, Mahmood U, et al
    Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
    Lung Cancer. 2017;108:222-227.
    PubMed     Text format     Abstract available


  183. RUIZ-BANOBRE J, Perez-Pampin E, Garcia-Gonzalez J, Gomez-Caamano A, et al
    Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature.
    Lung Cancer. 2017;108:217-221.
    PubMed     Text format     Abstract available


  184. WEHLER T, Thomas M, Schumann C, Bosch-Barrera J, et al
    A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
    Lung Cancer. 2017;108:212-216.
    PubMed     Text format     Abstract available


  185. DRIESSEN EJ, Aarts MJ, Bootsma GP, van Loon JG, et al
    Trends in treatment and relative survival among Non-Small Cell Lung Cancer patients in the Netherlands (1990-2014): Disparities between younger and older patients.
    Lung Cancer. 2017;108:198-204.
    PubMed     Text format     Abstract available


  186. YANG SC, Lai WW, Lin CC, Su WC, et al
    Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan.
    Lung Cancer. 2017;108:183-191.
    PubMed     Text format     Abstract available


  187. HARRIS JP, Patel MI, Loo BW, Wakelee HA, et al
    A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer.
    Lung Cancer. 2017;108:173-182.
    PubMed     Text format     Abstract available


  188. MORAN T, Palmero R, Provencio M, Insa A, et al
    A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
    Lung Cancer. 2017;108:154-160.
    PubMed     Text format     Abstract available


  189. MORABITO A, Daniele G, Costanzo R, Favaretto AG, et al
    A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
    Lung Cancer. 2017;108:15-21.
    PubMed     Text format     Abstract available


  190. PATEL MI, McKinley M, Cheng I, Haile R, et al
    Lung cancer incidence trends in California by race/ethnicity, histology, sex, and neighborhood socioeconomic status: An analysis spanning 28 years.
    Lung Cancer. 2017;108:140-149.
    PubMed     Text format     Abstract available


  191. KRON F, Kostenko A, Scheffler M, Muller D, et al
    Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center.
    Lung Cancer. 2017;108:134-139.
    PubMed     Text format     Abstract available


  192. KANAJI N, Sakai K, Ueda Y, Miyawaki H, et al
    Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease.
    Lung Cancer. 2017;108:126-133.
    PubMed     Text format     Abstract available


  193. PATEL SH, Rimner A, Foster A, Zhang Z, et al
    Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.
    Lung Cancer. 2017;108:109-114.
    PubMed     Text format     Abstract available


  194. MIKUBO M, Nakashima H, Naito M, Matsui Y, et al
    Prognostic impact of uncertain parietal pleural invasion at adhesion sites in non-small cell lung cancer patients.
    Lung Cancer. 2017;108:103-108.
    PubMed     Text format     Abstract available


    April 2017
  195. SIMMONS CP, Koinis F, Fallon MT, Fearon KC, et al
    Corrigendum to "Prognosis in advanced lung cancer - A prospective study examining key clinicopathological factors" [Lung Cancer 88 (2015) 304-309].
    Lung Cancer. 2017 Apr 27. pii: S0169-5002(17)30302.
    PubMed     Text format    


  196. TANAKA N, Toyooka S, Soh J, Kubo T, et al
    Erratum to "Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer" [Lung Cancer 76 (1) (2012) 32-38].
    Lung Cancer. 2017 Apr 27. pii: S0169-5002(16)30299.
    PubMed     Text format    


  197. EDWARDS T, Balata H, Foden P, Crosbie P, et al
    Research letter: Evaluating the future pathological N descriptors for lung cancer staging in a UK population.
    Lung Cancer. 2017 Apr 15. pii: S0169-5002(17)30295.
    PubMed     Text format    


  198. HOLBRECHTS S, Gorham J, Sideris S, Meert AP, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes.
    Lung Cancer. 2017;106:93-101.
    PubMed     Text format     Abstract available


  199. BENTEA G, Sculier C, Grigoriu B, Meert AP, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system.
    Lung Cancer. 2017;106:83-92.
    PubMed     Text format     Abstract available


  200. FUJIWARA A, Shintani Y, Funaki S, Kawamura T, et al
    Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer.
    Lung Cancer. 2017;106:8-16.
    PubMed     Text format     Abstract available


  201. KIM DW, Garon EB, Jatoi A, Keefe DM, et al
    Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
    Lung Cancer. 2017;106:76-82.
    PubMed     Text format     Abstract available


  202. REMON J, Pardo N, Martinez-Marti A, Cedres S, et al
    Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
    Lung Cancer. 2017;106:70-75.
    PubMed     Text format     Abstract available


  203. MADDISON P
    Effects of aspirin on small-cell lung cancer mortality and metastatic presentation.
    Lung Cancer. 2017;106:67-69.
    PubMed     Text format     Abstract available


  204. SIMMONS VN, Gray JE, Schabath MB, Wilson LE, et al
    High-risk community and primary care providers knowledge about and barriers to low-dose computed topography lung cancer screening.
    Lung Cancer. 2017;106:42-49.
    PubMed     Text format     Abstract available


  205. LIU M, Wampfler JA, Dai J, Gupta R, et al
    Chest wall resection for non-small cell lung cancer: A case-matched study of postoperative pulmonary function and quality of life.
    Lung Cancer. 2017;106:37-41.
    PubMed     Text format     Abstract available


  206. HALPENNY DF, McEvoy S, Li A, Hayan S, et al
    Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics.
    Lung Cancer. 2017;106:33-36.
    PubMed     Text format     Abstract available


  207. IRIKI T, Ohnishi K, Fujiwara Y, Horlad H, et al
    The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation.
    Lung Cancer. 2017;106:22-32.
    PubMed     Text format     Abstract available


  208. KASAHARA N, Kenmotsu H, Serizawa M, Umehara R, et al
    Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2017;106:138-144.
    PubMed     Text format     Abstract available


  209. JONES BS, Jerome MS, Miley D, Jackson BE, et al
    Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2017;106:125-130.
    PubMed     Text format     Abstract available


  210. OU SI, Lee TK, Young L, Fernandez-Rocha MY, et al
    Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
    Lung Cancer. 2017;106:110-114.
    PubMed     Text format     Abstract available


  211. DURIEUX V, Coureau M, Meert AP, Berghmans T, et al
    Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature.
    Lung Cancer. 2017;106:102-109.
    PubMed     Text format     Abstract available


  212. BAGLEY SJ, Kothari S, Aggarwal C, Bauml JM, et al
    Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2017;106:1-7.
    PubMed     Text format     Abstract available


  213. METRO G, Tazza M, Matocci R, Chiari R, et al
    Optimal management of ALK-positive NSCLC progressing on crizotinib.
    Lung Cancer. 2017;106:58-66.
    PubMed     Text format     Abstract available


  214. BASLER L, Kroeze SG, Guckenberger M
    SBRT for oligoprogressive oncogene addicted NSCLC.
    Lung Cancer. 2017;106:50-57.
    PubMed     Text format     Abstract available


  215. VANDERLAAN PA, Rangachari D, Mockus SM, Spotlow V, et al
    Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
    Lung Cancer. 2017;106:17-21.
    PubMed     Text format     Abstract available


  216. KWON D, Koh J, Kim S, Go H, et al
    MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
    Lung Cancer. 2017;106:131-137.
    PubMed     Text format     Abstract available


  217. HONG SW, Park NS, Noh MH, Shim JA, et al
    Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.
    Lung Cancer. 2017;106:115-124.
    PubMed     Text format     Abstract available


    March 2017
  218. LI H, Yang T, Ning Q, Shang D, et al
    MicroRNA-505 modulates cancer proliferation and migration in human non-small cell lung cancer through inverse regulation of FZD4.
    Lung Cancer. 2017 Mar 31. pii: S0169-5002(17)30270.
    PubMed     Text format     Abstract available


  219. CAPELLETTO E, Mariniello A, Novello S
    Targeted therapy in small cell lung cancer: A new era?
    Lung Cancer. 2017 Mar 12. pii: S0169-5002(17)30258.
    PubMed     Text format    


  220. SALGIA R, Stille JR, Weaver RW, McCleod M, et al
    A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
    Lung Cancer. 2017;105:7-13.
    PubMed     Text format     Abstract available


  221. VERONESI G, Colombo P, Novellis P, Crepaldi A, et al
    Pilot study on use of home telephoning to identify and recruit high-risk individuals for lung cancer screening.
    Lung Cancer. 2017;105:39-41.
    PubMed     Text format     Abstract available


  222. GACHECHILADZE M, Skarda J, Kolek V, Grygarkova I, et al
    Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients.
    Lung Cancer. 2017;105:31-38.
    PubMed     Text format     Abstract available


  223. KATAKAMI N, Hida T, Nokihara H, Imamura F, et al
    Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.
    Lung Cancer. 2017;105:23-30.
    PubMed     Text format     Abstract available


  224. SOO RA, Kim HR, Asuncion BR, Fazreen Z, et al
    Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2017;105:17-22.
    PubMed     Text format     Abstract available


  225. YONESAKA K, Hirotani K, von Pawel J, Dediu M, et al
    Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.
    Lung Cancer. 2017;105:1-6.
    PubMed     Text format     Abstract available


    February 2017
  226. TAYLOR KL, Hagerman CJ, Luta G, Bellini PG, et al
    Preliminary evaluation of a telephone-based smoking cessation intervention in the lung cancer screening setting: A randomized clinical trial.
    Lung Cancer. 2017 Feb 14. pii: S0169-5002(17)30029.
    PubMed     Text format     Abstract available


  227. SU XD, Xie HJ, Liu QW, Mo YX, et al
    The prognostic impact of tumor volume on stage I non-small cell lung cancer.
    Lung Cancer. 2017;104:91-97.
    PubMed     Text format     Abstract available


  228. SESUMI Y, Suda K, Mizuuchi H, Kobayashi Y, et al
    Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.
    Lung Cancer. 2017;104:85-90.
    PubMed     Text format     Abstract available


  229. KAWAGUCHI K, Yokoi K, Niwa H, Ohde Y, et al
    A prospective, multi-institutional phase II study of induction chemoradiotherapy followed by surgery in patients with non-small cell lung cancer involving the chest wall (CJLSG0801).
    Lung Cancer. 2017;104:79-84.
    PubMed     Text format     Abstract available


  230. AWAN S, Crosby V, Potter V, Hennig I, et al
    Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study.
    Lung Cancer. 2017;104:75-78.
    PubMed     Text format     Abstract available


  231. CHANG GC, Tseng CH, Hsu KH, Yu CJ, et al
    Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Lung Cancer. 2017;104:58-64.
    PubMed     Text format     Abstract available


  232. LAM VK, Bentzen SM, Mohindra P, Nichols EM, et al
    Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC).
    Lung Cancer. 2017;104:52-57.
    PubMed     Text format     Abstract available


  233. PAZ-ARES LG, Zimmermann A, Ciuleanu T, Bunn PA, et al
    Meta-analysis examining impact of age on overall survival with pemetrexed for the treatment of advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2017;104:45-51.
    PubMed     Text format     Abstract available


  234. LILLIE SE, Fu SS, Fabbrini AE, Rice KL, et al
    What factors do patients consider most important in making lung cancer screening decisions? Findings from a demonstration project conducted in the Veterans Health Administration.
    Lung Cancer. 2017;104:38-44.
    PubMed     Text format     Abstract available


  235. KOH YW, Lee SJ, Park SY
    Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters.
    Lung Cancer. 2017;104:31-37.
    PubMed     Text format     Abstract available


  236. MESSARITAKIS I, Politaki E, Plataki M, Karavassilis V, et al
    Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.
    Lung Cancer. 2017;104:16-23.
    PubMed     Text format     Abstract available


  237. AWAD MM, Chu QS, Gandhi L, Stephenson JJ, et al
    An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).
    Lung Cancer. 2017;104:126-130.
    PubMed     Text format     Abstract available


  238. KATO T, Masuda N, Nakanishi Y, Takahashi M, et al
    Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
    Lung Cancer. 2017;104:111-118.
    PubMed     Text format     Abstract available


  239. SHIN B, Shin S, Chung MJ, Lee H, et al
    Different histological subtypes of peripheral lung cancer based on emphysema distribution in patients with both airflow limitation and CT-determined emphysema.
    Lung Cancer. 2017;104:106-110.
    PubMed     Text format     Abstract available


  240. OKUMA Y, Hosomi Y, Nakahara Y, Watanabe K, et al
    High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
    Lung Cancer. 2017;104:1-6.
    PubMed     Text format     Abstract available


  241. HIDA T, Hamasaki M, Matsumoto S, Sato A, et al
    Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry.
    Lung Cancer. 2017;104:98-105.
    PubMed     Text format     Abstract available


  242. SAKAGUCHI H, Ishida H, Nitanda H, Yamazaki N, et al
    Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.
    Lung Cancer. 2017;104:70-74.
    PubMed     Text format     Abstract available


  243. TAKADA K, Okamoto T, Toyokawa G, Kozuma Y, et al
    The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Lung Cancer. 2017;104:7-15.
    PubMed     Text format     Abstract available


  244. LAURIE SA, Hao D, Leighl NB, Goffin J, et al
    A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
    Lung Cancer. 2017;104:65-69.
    PubMed     Text format     Abstract available


  245. WU YL, Saijo N, Thongprasert S, Yang JC, et al
    Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
    Lung Cancer. 2017;104:119-125.
    PubMed     Text format     Abstract available


    January 2017
  246. SLOTMAN B
    What is the optimal radiotherapy schedule for limited stage small cell lung cancer?
    Lung Cancer. 2017 Jan 4. pii: S0169-5002(17)30002.
    PubMed     Text format     Abstract available


  247. GOW CH, Hsieh MS, Wu SG, Shih JY, et al
    A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
    Lung Cancer. 2017;103:82-89.
    PubMed     Text format     Abstract available


  248. THOMAS DC, Arnold BN, Rosen JE, Salazar MC, et al
    Defining outcomes of patients with clinical stage I small cell lung cancer upstaged at surgery.
    Lung Cancer. 2017;103:75-81.
    PubMed     Text format     Abstract available


  249. KANISKI F, Enewold L, Thomas A, Malik S, et al
    Temporal patterns of care and outcomes of non-small cell lung cancer patients in the United States diagnosed in 1996, 2005, and 2010.
    Lung Cancer. 2017;103:66-74.
    PubMed     Text format     Abstract available


  250. SAMSON P, Keogan K, Crabtree T, Colditz G, et al
    Interpreting survival data from clinical trials of surgery versus stereotactic body radiation therapy in operable Stage I non-small cell lung cancer patients.
    Lung Cancer. 2017;103:6-10.
    PubMed     Text format     Abstract available


  251. MCGOWAN M, Hoven AS, Lund-Iversen M, Solberg S, et al
    PIK3CA mutations as prognostic factor in squamous cell lung carcinoma.
    Lung Cancer. 2017;103:52-57.
    PubMed     Text format     Abstract available


  252. REUNGWETWATTANA T, Liang Y, Zhu V, Ou SI, et al
    The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Lung Cancer. 2017;103:27-37.
    PubMed     Text format     Abstract available


  253. STAHL JM, Corso CD, Verma V, Park HS, et al
    Trends in stereotactic body radiation therapy for stage I small cell lung cancer.
    Lung Cancer. 2017;103:11-16.
    PubMed     Text format     Abstract available


  254. VON LAFFERT M, Schirmacher P, Warth A, Weichert W, et al
    ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer So
    Lung Cancer. 2017;103:1-5.
    PubMed     Text format     Abstract available


  255. TO KK, Tong WS, Fu LW
    Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
    Lung Cancer. 2017;103:58-65.
    PubMed     Text format     Abstract available


  256. TSIM S, Stobo DB, Alexander L, Kelly C, et al
    The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy.
    Lung Cancer. 2017;103:38-43.
    PubMed     Text format     Abstract available


    December 2016
  257. MALIK N, Palma D
    Oligometastatic non-small cell lung cancer: Where do we go next?
    Lung Cancer. 2016 Dec 26. pii: S0169-5002(16)30581.
    PubMed     Text format    


  258. VRANCKEN A, Lepers S, Peeters L, Oyen C, et al
    The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database.
    Lung Cancer. 2016;102:96-100.
    PubMed     Text format     Abstract available


  259. HALVORSEN TO, Herje M, Levin N, Bremnes RM, et al
    Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer.
    Lung Cancer. 2016;102:9-14.
    PubMed     Text format     Abstract available


  260. LEE SH, Sung JY, Yong D, Chun J, et al
    Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions.
    Lung Cancer. 2016;102:89-95.
    PubMed     Text format     Abstract available


  261. HANNA NH, Kaiser R, Sullivan RN, Aren OR, et al
    Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
    Lung Cancer. 2016;102:65-73.
    PubMed     Text format     Abstract available


  262. TOMIZAWA K, Nishino M, Sesumi Y, Kobayashi Y, et al
    Prognostic impact of pleural lavage cytology in patients with primary lung cancer.
    Lung Cancer. 2016;102:60-64.
    PubMed     Text format     Abstract available


  263. GUPTA A, Majumder K, Arora N, Mayo HG, et al
    Premorbid body mass index and mortality in patients with lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2016;102:49-59.
    PubMed     Text format     Abstract available


  264. TANIZAKI J, Hayashi H, Kimura M, Tanaka K, et al
    Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression.
    Lung Cancer. 2016;102:44-48.
    PubMed     Text format     Abstract available


  265. LEVACQ D, D'Haene N, de Wind R, Remmelink M, et al
    Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.
    Lung Cancer. 2016;102:38-41.
    PubMed     Text format     Abstract available


  266. CICENAS S, Geater SL, Petrov P, Hotko Y, et al
    Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).
    Lung Cancer. 2016;102:30-37.
    PubMed     Text format     Abstract available


  267. LE FOURNIS S, Gohier P, Urban T, Jeanfaivre T, et al
    Corneal graft rejection in a patient treated with nivolumab for primary lung cancer.
    Lung Cancer. 2016;102:28-29.
    PubMed     Text format     Abstract available


  268. FUKUDA S, Oguri T, Kunii E, Sone K, et al
    A folylpoly-gamma-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer.
    Lung Cancer. 2016;102:15-20.
    PubMed     Text format     Abstract available


  269. DAI SD, Wang Y, Jiang GY, Zhang PX, et al
    RETRACTED: Kaiso is expressed in lung cancer: Its expression and localization is affected by p120ctn.
    Lung Cancer. 2016;102:141.
    PubMed     Text format    


  270. CHAPMAN AM, Sun KY, Ruestow P, Cowan DM, et al
    Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.
    Lung Cancer. 2016;102:122-134.
    PubMed     Text format     Abstract available


  271. WONG ML, McMurry TL, Stukenborg GJ, Francescatti AB, et al
    Impact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: A nationally representative cohort study.
    Lung Cancer. 2016;102:108-117.
    PubMed     Text format     Abstract available


    November 2016
  272. ROLFO C, Giallombardo M, Reclusa P, Sirera R, et al
    Exosomes in lung cancer liquid biopsies: Two sides of the same coin?
    Lung Cancer. 2016 Nov 18. pii: S0169-5002(16)30530.
    PubMed     Text format    


  273. GOFFIN JR, Flanagan WM, Miller AB, Fitzgerald NR, et al
    Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.
    Lung Cancer. 2016;101:98-103.
    PubMed     Text format     Abstract available


  274. SUZUKI Y, Okamoto T, Fujishita T, Katsura M, et al
    Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer.
    Lung Cancer. 2016;101:92-97.
    PubMed     Text format     Abstract available


  275. OHGAMI M, Kaburagi T, Kurosawa A, Homma M, et al
    Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer.
    Lung Cancer. 2016;101:9-10.
    PubMed     Text format     Abstract available


  276. BERNHARDT D, Bozorgmehr F, Adeberg S, Opfermann N, et al
    Outcome in patients with small cell lung cancer re-irradiated for brain metastases after prior prophylactic cranial irradiation.
    Lung Cancer. 2016;101:76-81.
    PubMed     Text format     Abstract available


  277. HENDRIKS LE, Brouns AJ, Amini M, Uyterlinde W, et al
    Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
    Lung Cancer. 2016;101:68-75.
    PubMed     Text format     Abstract available


  278. KIM JY, Sun V, Raz DJ, Williams AC, et al
    The impact of lung cancer surgery on quality of life trajectories in patients and family caregivers.
    Lung Cancer. 2016;101:35-39.
    PubMed     Text format     Abstract available


  279. VERONESI G, Novellis P, Voulaz E, Alloisio M, et al
    Robot-assisted surgery for lung cancer: State of the art and perspectives.
    Lung Cancer. 2016;101:28-34.
    PubMed     Text format     Abstract available


  280. THONGPRASERT S, Yang PC, Lee JS, Soo R, et al
    The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients.
    Lung Cancer. 2016;101:137-144.
    PubMed     Text format     Abstract available


  281. NUMAN RC, Berge MT, Burgers JA, Klomp HM, et al
    Peri- and postoperative management of stage I-III Non Small Cell Lung Cancer: Which quality of care indicators are evidence-based?
    Lung Cancer. 2016;101:129-136.
    PubMed     Text format     Abstract available


  282. LAM SK, Leung LL, Li YY, Zheng CY, et al
    Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
    Lung Cancer. 2016;101:111-119.
    PubMed     Text format     Abstract available


  283. TANIZAKI J, Banno E, Togashi Y, Hayashi H, et al
    Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
    Lung Cancer. 2016;101:11-15.
    PubMed     Text format     Abstract available


  284. NOSAKI K, Satouchi M, Kurata T, Yoshida T, et al
    Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study.
    Lung Cancer. 2016;101:1-8.
    PubMed     Text format     Abstract available


    October 2016
  285. REMON J, Girard N, Mazieres J, Dansin E, et al
    Erratum to "Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network" [Lung Cancer, 97 (July 2016), 99-104].
    Lung Cancer. 2016 Oct 6. pii: S0169-5002(16)30483.
    PubMed     Text format    


  286. VANNUCCI F, Gonzalez-Rivas D
    Is VATS lobectomy standard of care for operable non-small cell lung cancer?
    Lung Cancer. 2016;100:114-9.
    PubMed     Text format     Abstract available


  287. BAUML JM, Troxel A, Epperson CN, Cohen RB, et al
    Scan-associated distress in lung cancer: Quantifying the impact of "scanxiety".
    Lung Cancer. 2016;100:110-3.
    PubMed     Text format     Abstract available


  288. SULLIVAN DR, Forsberg CW, Ganzini L, Au DH, et al
    Depression symptom trends and health domains among lung cancer patients in the CanCORS study.
    Lung Cancer. 2016;100:102-9.
    PubMed     Text format     Abstract available


  289. JEPPESEN SS, Hansen NC, Schytte T, Nielsen M, et al
    Comparison of survival of chronic obstructive pulmonary disease patients with or without a localized non-small cell lung cancer.
    Lung Cancer. 2016;100:90-5.
    PubMed     Text format     Abstract available


  290. MITIN T, Jain A, Degnin C, Chen Y, et al
    Current patterns of care for patients with extensive stage small cell lung cancer: Survey of US radiation oncologists on their recommendations regarding thoracic consolidation radiotherapy.
    Lung Cancer. 2016;100:85-9.
    PubMed     Text format     Abstract available


  291. SORENSEN SF, Demuth C, Weber B, Sorensen BS, et al
    Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.
    Lung Cancer. 2016;100:77-84.
    PubMed     Text format     Abstract available


  292. KLUPCZYNSKA A, Derezinski P, Dyszkiewicz W, Pawlak K, et al
    Evaluation of serum amino acid profiles' utility in non-small cell lung cancer detection in Polish population.
    Lung Cancer. 2016;100:71-6.
    PubMed     Text format     Abstract available


  293. JIANG T, Zhai C, Su C, Ren S, et al
    The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis.
    Lung Cancer. 2016;100:63-70.
    PubMed     Text format     Abstract available


  294. GIBELIN C, Couraud S
    Somatic alterations in lung cancer: Do environmental factors matter?
    Lung Cancer. 2016;100:45-52.
    PubMed     Text format     Abstract available


  295. NEUMAIR P, Joos L, Warschkow R, Dutly A, et al
    Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study.
    Lung Cancer. 2016;100:38-44.
    PubMed     Text format     Abstract available


  296. SCAGLIOTTI G, Nishio M, Satouchi M, Valmadre G, et al
    A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy.
    Lung Cancer. 2016;100:20-3.
    PubMed     Text format     Abstract available


    September 2016
  297. ERB CT, Su KW, Soulos PR, Tanoue LT, et al
    Surveillance Practice Patterns after Curative Intent Therapy for Stage I Non-Small-Cell Lung Cancer in the Medicare Population.
    Lung Cancer. 2016;99:200-7.
    PubMed     Text format     Abstract available


  298. YOH K, Hosomi Y, Kasahara K, Yamada K, et al
    A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
    Lung Cancer. 2016;99:186-93.
    PubMed     Text format     Abstract available


  299. DAWE DE, Christiansen D, Swaminath A, Ellis PM, et al
    Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2016;99:180-5.
    PubMed     Text format     Abstract available


  300. DAI L, Tsay JC, Li J, Yie TA, et al
    Autoantibodies against tumor-associated antigens in the early detection of lung cancer.
    Lung Cancer. 2016;99:172-9.
    PubMed     Text format     Abstract available


  301. LIN JJ, Ezer N, Sigel K, Mhango G, et al
    The effect of statins on survival in patients with stage IV lung cancer.
    Lung Cancer. 2016;99:137-42.
    PubMed     Text format     Abstract available


  302. USUI K, Sugawara S, Nishitsuji M, Fujita Y, et al
    A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A.
    Lung Cancer. 2016;99:131-6.
    PubMed     Text format     Abstract available


  303. GAINETDINOV IV, Kapitskaya KY, Rykova EY, Ponomaryova AA, et al
    Hypomethylation of human-specific family of LINE-1 retrotransposons in circulating DNA of lung cancer patients.
    Lung Cancer. 2016;99:127-30.
    PubMed     Text format     Abstract available


  304. TABCHI S, Weng X, Blais N
    Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab.
    Lung Cancer. 2016;99:123-6.
    PubMed     Text format     Abstract available


  305. SAKATA Y, Kawamura K, Shingu N, Ichikado K, et al
    Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.
    Lung Cancer. 2016;99:120-2.
    PubMed     Text format     Abstract available


  306. SMIT EF, Wu YL, Gervais R, Zhou C, et al
    A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).
    Lung Cancer. 2016;99:94-101.
    PubMed     Text format     Abstract available


  307. SALANDER P, Lilliehorn S
    To carry on as before: A meta-synthesis of qualitative studies in lung cancer.
    Lung Cancer. 2016;99:88-93.
    PubMed     Text format     Abstract available


  308. SHIEN K, Papadimitrakopoulou VA, Wistuba II
    Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
    Lung Cancer. 2016;99:79-87.
    PubMed     Text format     Abstract available


  309. SHALLWANI SM, Simmonds MJ, Kasymjanova G, Spahija J, et al
    Quality of life, symptom status and physical performance in patients with advanced non-small cell lung cancer undergoing chemotherapy: an exploratory analysis of secondary data.
    Lung Cancer. 2016;99:69-75.
    PubMed     Text format     Abstract available


  310. KIM HR, Lee GO, Choi KH, Kim DK, et al
    SRSF5: a novel marker for small-cell lung cancer and pleural metastatic cancer.
    Lung Cancer. 2016;99:57-65.
    PubMed     Text format     Abstract available


  311. WIDLAK P, Pietrowska M, Polanska J, Marczyk M, et al
    Serum mass profile signature as a biomarker of early lung cancer.
    Lung Cancer. 2016;99:46-52.
    PubMed     Text format     Abstract available


  312. SAKATA S, Saeki S, Okamoto I, Otsubo K, et al
    Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.
    Lung Cancer. 2016;99:41-5.
    PubMed     Text format     Abstract available


  313. JOHNSON AC, Do P, Richard N, Dubos C, et al
    Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.
    Lung Cancer. 2016;99:38-40.
    PubMed     Text format     Abstract available


  314. CAPPUZZO F, Morabito A, Normanno N, Bidoli P, et al
    Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2016;99:31-7.
    PubMed     Text format     Abstract available


  315. PIETANZA MC, Litvak AM, Varghese AM, Krug LM, et al
    A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer.
    Lung Cancer. 2016;99:23-30.
    PubMed     Text format     Abstract available


  316. ZENKE Y, Umemura S, Sugiyama E, Kirita K, et al
    Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer.
    Lung Cancer. 2016;99:1-3.
    PubMed     Text format     Abstract available


    August 2016
  317. LACCETTI AL, Pruitt SL, Xuan L, Halm EA, et al
    Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis.
    Lung Cancer. 2016;98:106-13.
    PubMed     Text format     Abstract available


  318. CHEN YM, Lai CH, Rau KM, Huang CH, et al
    Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.
    Lung Cancer. 2016;98:99-105.
    PubMed     Text format     Abstract available


  319. PINEIRO B, Simmons VN, Palmer AM, Correa JB, et al
    Smoking cessation interventions within the context of Low-Dose Computed Tomography lung cancer screening: A systematic review.
    Lung Cancer. 2016;98:91-8.
    PubMed     Text format     Abstract available


  320. MONNET I, Audigier-Valette C, Girard N, Vergnenegre A, et al
    Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.
    Lung Cancer. 2016;98:84-90.
    PubMed     Text format     Abstract available


  321. BOYER MJ, Gu L, Wang X, Kelsey CR, et al
    Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer.
    Lung Cancer. 2016;98:76-8.
    PubMed     Text format     Abstract available


  322. SHIMOJI M, Shimizu S, Sato K, Suda K, et al
    Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
    Lung Cancer. 2016;98:69-75.
    PubMed     Text format     Abstract available


  323. LI SY, Li Q, Guan WJ, Huang J, et al
    Effects of para-toluenesulfonamide intratumoral injection on non-small cell lung carcinoma with severe central airway obstruction: A multi-center, non-randomized, single-arm, open-label trial.
    Lung Cancer. 2016;98:43-50.
    PubMed     Text format     Abstract available


  324. ZANETTI KA, Wang Z, Aldrich M, Amos CI, et al
    Genome-wide association study confirms lung cancer susceptibility loci on chromosomes 5p15 and 15q25 in an African-American population.
    Lung Cancer. 2016;98:33-42.
    PubMed     Text format     Abstract available


  325. SHOJI F, Morodomi Y, Akamine T, Takamori S, et al
    Predictive impact for postoperative recurrence using the preoperative prognostic nutritional index in pathological stage I non-small cell lung cancer.
    Lung Cancer. 2016;98:15-21.
    PubMed     Text format     Abstract available


  326. CADRANEL J, Park K, Arrieta O, Pless M, et al
    Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
    Lung Cancer. 2016;98:9-14.
    PubMed     Text format     Abstract available


  327. MOK T, Ladrera G, Srimuninnimit V, Sriuranpong V, et al
    Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.
    Lung Cancer. 2016;98:1-8.
    PubMed     Text format     Abstract available


    July 2016
  328. HIDDINGA BI, Pauwels P, Janssens A, van Meerbeeck JP, et al
    O6-Methylguanine-DNA methyltransferase (MGMT): A drugable target in lung cancer?
    Lung Cancer. 2016 Jul 18. pii: S0169-5002(16)30412.
    PubMed     Text format     Abstract available


  329. PHILIPPOV PP
    Express of concern on 'Antirecoverin autoantibodies in the patient with non-small cell lung cancer but without cancer-associated retinopathy'.
    Lung Cancer. 2016 Jul 13. pii: S0169-5002(16)30399.
    PubMed     Text format    


  330. HU H, Xu Z, Li C, Xu C, et al
    MiR-145 and miR-203 represses TGF-beta-induced epithelial-mesenchymal transition and invasion by inhibiting SMAD3 in non-small cell lung cancer cells.
    Lung Cancer. 2016;97:87-94.
    PubMed     Text format     Abstract available


  331. GARCIA-VELLOSO MJ, Bastarrika G, de-Torres JP, Lozano MD, et al
    Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT.
    Lung Cancer. 2016;97:81-6.
    PubMed     Text format     Abstract available


  332. COSTA G, Thuler LC, Ferreira CG
    Epidemiological changes in the histological subtypes of 35,018 non-small-cell lung cancer cases in Brazil.
    Lung Cancer. 2016;97:66-72.
    PubMed     Text format     Abstract available


  333. YOSHIDA T, Oya Y, Tanaka K, Shimizu J, et al
    Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer.
    Lung Cancer. 2016;97:43-7.
    PubMed     Text format     Abstract available


  334. SANCHEZ-SALCEDO P, de-Torres JP, Martinez-Urbistondo D, Gonzalez-Gutierrez J, et al
    The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development.
    Lung Cancer. 2016;97:28-34.
    PubMed     Text format     Abstract available


  335. BRULE SY, Al-Baimani K, Jonker H, Zhang T, et al
    Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.
    Lung Cancer. 2016;97:15-21.
    PubMed     Text format     Abstract available


  336. KENNEDY MP, Hall PS, Callister ME
    Factors affecting hospital costs in lung cancer patients in the United Kingdom.
    Lung Cancer. 2016;97:8-14.
    PubMed     Text format     Abstract available


  337. NAKAGAWA K, Asamura H, Tsuta K, Nagai K, et al
    The novel one-step nucleic acid amplification (OSNA) assay for the diagnosis of lymph node metastasis in patients with non-small cell lung cancer (NSCLC): Results of a multicenter prospective study.
    Lung Cancer. 2016;97:1-7.
    PubMed     Text format     Abstract available


    June 2016
  338. ROBLES AI, Harris CC
    Integration of multiple "OMIC" biomarkers: A precision medicine strategy for lung cancer.
    Lung Cancer. 2016 Jun 14. pii: S0169-5002(16)30361.
    PubMed     Text format     Abstract available


  339. ROTHSCHILD SI, Gautschi O, Batliner J, Gugger M, et al
    MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
    Lung Cancer. 2016 Jun 14. pii: S0169-5002(16)30362.
    PubMed     Text format     Abstract available


  340. FINAN KM, Hodge G, Reynolds AM, Hodge S, et al
    Corrigendum to "In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2" [Lung Cancer 53 (3) (September 2006) 273-284].
    Lung Cancer. 2016 Jun 13. pii: S0169-5002(16)30360.
    PubMed     Text format    


  341. LI J, Yu J, Liu A, Wang Y, et al
    Retraction notice to "ss-elemene against human lung cancer via up-regulation of P53 protein expression to promote the release of exosome": LUNG 86/2 (2014) 144-150.
    Lung Cancer. 2016;96:120.
    PubMed     Text format    


  342. WEISS E, Ford JC, Olsen KM, Karki K, et al
    Apparent diffusion coefficient (ADC) change on repeated diffusion-weighted magnetic resonance imaging during radiochemotherapy for non-small cell lung cancer: A pilot study.
    Lung Cancer. 2016;96:113-9.
    PubMed     Text format     Abstract available


  343. HAN JY, Kim HY, Lim KY, Hwangbo B, et al
    A phase II study of nintedanib in patients with relapsed small cell lung cancer.
    Lung Cancer. 2016;96:108-12.
    PubMed     Text format     Abstract available


  344. HSU F, De Caluwe A, Anderson D, Nichol A, et al
    EGFR mutation status on brain metastases from non-small cell lung cancer.
    Lung Cancer. 2016;96:101-7.
    PubMed     Text format     Abstract available


  345. ZHOU L, He J, Xiong W, Liu Y, et al
    Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
    Lung Cancer. 2016;96:93-100.
    PubMed     Text format     Abstract available


  346. XU J, Jin B, Chu T, Dong X, et al
    EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
    Lung Cancer. 2016;96:87-92.
    PubMed     Text format     Abstract available


  347. CREQUIT P, Ruppert AM, Rozensztajn N, Gounant V, et al
    EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
    Lung Cancer. 2016;96:74-7.
    PubMed     Text format     Abstract available


  348. ENOMOTO Y, Inui N, Kato T, Baba T, et al
    Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
    Lung Cancer. 2016;96:63-7.
    PubMed     Text format     Abstract available


  349. KIM HK, Cho JH, Choi YS, Zo JI, et al
    Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.
    Lung Cancer. 2016;96:56-62.
    PubMed     Text format     Abstract available


  350. LI R, Hermann G, Baldini E, Chen A, et al
    Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer.
    Lung Cancer. 2016;96:41-7.
    PubMed     Text format     Abstract available


  351. KHAKWANI A, Hubbard RB, Beckett P, Borthwick D, et al
    Which patients are assessed by lung cancer nurse specialists? A national lung cancer audit study of over 128,000 patients across england.
    Lung Cancer. 2016;96:33-40.
    PubMed     Text format     Abstract available


  352. PATIL T, Aisner DL, Noonan SA, Bunn PA, et al
    Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status.
    Lung Cancer. 2016;96:27-32.
    PubMed     Text format     Abstract available


  353. SAKURAI S, Shirai T, Akamatsu T, Hayashi I, et al
    Endobronchial lesions as a predictor of impaired cough-related quality of life in lung cancer.
    Lung Cancer. 2016;96:25-6.
    PubMed     Text format    


  354. OLIVEIRA MB, Mello FC, Paschoal ME
    The relationship between lung cancer histology and the clinicopathological characteristics of bone metastases.
    Lung Cancer. 2016;96:19-24.
    PubMed     Text format     Abstract available


  355. BENAVENT F, Capobianco CS, Garona J, Cirigliano SM, et al
    CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.
    Lung Cancer. 2016 Jun 1. pii: S0169-5002(16)30352.
    PubMed     Text format     Abstract available


    May 2016
  356. VAVALA T, Monica V, Lo Iacono M, Mele T, et al
    Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research.
    Lung Cancer. 2016 May 31. pii: S0169-5002(16)30348.
    PubMed     Text format     Abstract available


  357. TARTARONE A, Rossi E, Lerose R, Mambella G, et al
    Possible applications of circulating tumor cells in patients with non small cell lung cancer.
    Lung Cancer. 2016 May 31. pii: S0169-5002(16)30349.
    PubMed     Text format     Abstract available


  358. KOMIYA K, Sueoka-Aragane N, Sato A, Hisatomi T, et al
    Erratum to "Expression of Mina53, a novel c-Myc target gene, is a favorable prognostic marker in early stage lung cancer" [Lung Cancer 69/2 (2010) 232-238].
    Lung Cancer. 2016 May 27. pii: S0169-5002(16)30318.
    PubMed     Text format    


  359. AKCA H, Demiray A, Tokgun O, Yokota J, et al
    Erratum to "Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells" [Lung Cancer 73 (3) (2011) 302-309].
    Lung Cancer. 2016 May 24. pii: S0169-5002(16)30319.
    PubMed     Text format    


  360. DAUTZENBERG B, Garelik D
    Patients with lung cancer: Are electronic cigarettes harmful or useful?
    Lung Cancer. 2016 May 20. pii: S0169-5002(16)30323.
    PubMed     Text format     Abstract available


  361. SIWICKY MD, Petrik JJ, Moorehead RA
    Erratum to "The function of IGF-IR in NNK-mediated lung tumorigenesis" [Lung Cancer 71 (1) (2011) 11-18].
    Lung Cancer. 2016 May 5. pii: S0169-5002(16)30306.
    PubMed     Text format    


  362. SORBER L, Zwaenepoel K, Deschoolmeester V, Van Schil PE, et al
    Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Lung Cancer. 2016 May 4. pii: S0169-5002(16)30312.
    PubMed     Text format     Abstract available


  363. O'DOWD EL, Luchtenborg M, Baldwin DR, McKeever TM, et al
    Predicting death from surgery for lung cancer: A comparison of two scoring systems in two European countries.
    Lung Cancer. 2016;95:88-93.
    PubMed     Text format     Abstract available


  364. VAVALA T, Follador A, Tiseo M, Galetta D, et al
    BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.
    Lung Cancer. 2016;95:73-81.
    PubMed     Text format     Abstract available


  365. KANG HN, Kim SH, Yun MR, Kim HR, et al
    ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.
    Lung Cancer. 2016;95:57-64.
    PubMed     Text format     Abstract available


  366. KUDJAWU YC, Chatellier G, Decool E, de Maria F, et al
    Timing in initiating lung cancer treatment after bronchoscopy in France: Study from medico-administrative database.
    Lung Cancer. 2016;95:44-50.
    PubMed     Text format     Abstract available


  367. DOESCH J, Debus D, Meyer C, Papadopoulos T, et al
    Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.
    Lung Cancer. 2016;95:35-8.
    PubMed     Text format     Abstract available


  368. SCHROEDER MC, Tien YY, Wright K, Halfdanarson TR, et al
    Geographic variation in the use of adjuvant therapy among elderly patients with resected non-small cell lung cancer.
    Lung Cancer. 2016;95:28-34.
    PubMed     Text format     Abstract available


  369. BRENNER DR, Yannitsos DH, Farris MS, Johansson M, et al
    Leisure-time physical activity and lung cancer risk: A systematic review and meta-analysis.
    Lung Cancer. 2016;95:17-27.
    PubMed     Text format     Abstract available


  370. MOTH E, McLachlan SA, Veillard AS, Muljadi N, et al
    Patients' preferred and perceived roles in making decisions about adjuvant chemotherapy for non-small-cell lung cancer.
    Lung Cancer. 2016;95:8-14.
    PubMed     Text format     Abstract available


  371. BUTNOR KJ, Brownlee NA, Mahar A, Pavlisko EN, et al
    Diffuse malignant mesothelioma and synchronous lung cancer: A clinicopathological study of 18 cases.
    Lung Cancer. 2016;95:1-7.
    PubMed     Text format     Abstract available


  372. JU L, Han M, Zhao C, Li X, et al
    EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient.
    Lung Cancer. 2016;95:94-7.
    PubMed     Text format     Abstract available


  373. METRO G, Ricciuti B, Chiari R, Baretti M, et al
    Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.
    Lung Cancer. 2016;95:82-7.
    PubMed     Text format     Abstract available


  374. SIEGELE BJ, Shilo K, Chao BH, Carbone DP, et al
    Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: Two cases and a review of the literature.
    Lung Cancer. 2016;95:65-72.
    PubMed     Text format     Abstract available


  375. SAKAKURA N, Inaba Y, Yatabe Y, Mizuno T, et al
    Estimation of the pathological invasive size of pulmonary adenocarcinoma using high-resolution computed tomography of the chest: A consideration based on lung and mediastinal window settings.
    Lung Cancer. 2016;95:51-6.
    PubMed     Text format     Abstract available


  376. WANG Q, Zhao L, Yang X, Wei S, et al
    Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.
    Lung Cancer. 2016;95:39-43.
    PubMed     Text format     Abstract available


  377. SASSIER M, Mennecier B, Gschwend A, Rein M, et al
    Successful treatment with ceritinib after crizotinib induced hepatitis.
    Lung Cancer. 2016;95:15-6.
    PubMed     Text format     Abstract available


    April 2016
  378. LUNG J, Lin YC, Hung MS, Jiang YY, et al
    A sensitive and high throughput TaqMan-based reverse transcription quantitative polymerase chain reaction assay efficiently discriminates ALK rearrangement from overexpression for lung cancer FFPE specimens.
    Lung Cancer. 2016;94:114-20.
    PubMed     Text format     Abstract available


  379. DICKHOFF C, Dahele M, Paul MA, van de Ven PM, et al
    Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer.
    Lung Cancer. 2016;94:108-13.
    PubMed     Text format     Abstract available


  380. ROSELL A, Rodriguez N, Monso E, Taron M, et al
    Aberrant gene methylation and bronchial dysplasia in high risk lung cancer patients.
    Lung Cancer. 2016;94:102-7.
    PubMed     Text format     Abstract available


  381. VAN DER AALST CM, de Koning HJ
    Biochemical verification of the self-reported smoking status of screened male smokers of the Dutch-Belgian randomized controlled lung cancer screening trial.
    Lung Cancer. 2016;94:96-101.
    PubMed     Text format     Abstract available


  382. CAMERON SJ, Lewis KE, Beckmann M, Allison GG, et al
    The metabolomic detection of lung cancer biomarkers in sputum.
    Lung Cancer. 2016;94:88-95.
    PubMed     Text format     Abstract available


  383. DUDANI S, Leighl NB, Ho C, Pantarotto JR, et al
    Approach to the non-operative management of patients with stage II non-small cell lung cancer (NSCLC): A survey of Canadian medical and radiation oncologists.
    Lung Cancer. 2016;94:74-80.
    PubMed     Text format     Abstract available


  384. IMAMURA F, Uchida J, Kukita Y, Kumagai T, et al
    Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.
    Lung Cancer. 2016;94:68-73.
    PubMed     Text format     Abstract available


  385. LOUIE AV, Damhuis RA, Haasbeek CJ, Warner A, et al
    Treatment and survival of second primary early-stage lung cancer, following treatment of head and neck cancer in the Netherlands.
    Lung Cancer. 2016;94:54-60.
    PubMed     Text format     Abstract available


  386. CHEN LY, Molina-Vila MA, Ruan SY, Su KY, et al
    Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2016;94:46-53.
    PubMed     Text format     Abstract available


  387. MENAMIN UC, Cardwell CR, Hughes CM, Murray LM, et al
    Metformin use and survival from lung cancer: A population-based cohort study.
    Lung Cancer. 2016;94:35-9.
    PubMed     Text format     Abstract available


  388. YIN Z, Cui Z, Ren Y, Xia L, et al
    Association between polymorphisms in pre-miRNA genes and risk of lung cancer in a Chinese non-smoking female population.
    Lung Cancer. 2016;94:15-21.
    PubMed     Text format     Abstract available


  389. SZYSZKO TA, Yip C, Szlosarek P, Goh V, et al
    The role of new PET tracers for lung cancer.
    Lung Cancer. 2016;94:7-14.
    PubMed     Text format     Abstract available


    March 2016
  390. PEROL M, Ciuleanu TE, Arrieta O, Prabhash K, et al
    Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
    Lung Cancer. 2016;93:95-103.
    PubMed     Text format     Abstract available


  391. TAVARES E CASTRO A, Clemente J, Carvalho L, Freitas S, et al
    Small-cell lung cancer in never-smokers: A case series.
    Lung Cancer. 2016;93:82-7.
    PubMed     Text format     Abstract available


  392. HIROSE T, Fujita K, Kusumoto S, Oki Y, et al
    Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
    Lung Cancer. 2016;93:69-76.
    PubMed     Text format     Abstract available


  393. TAN CS, Cho BC, Soo RA
    Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Lung Cancer. 2016;93:59-68.
    PubMed     Text format     Abstract available


  394. CHEN YM, Lai CH, Chang HC, Chao TY, et al
    The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors.
    Lung Cancer. 2016;93:47-54.
    PubMed     Text format     Abstract available


  395. HORIIKE A, Takeuchi K, Uenami T, Kawano Y, et al
    Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
    Lung Cancer. 2016;93:43-6.
    PubMed     Text format     Abstract available


  396. TONNIES S, Tonnies M, Kollmeier J, Bauer TT, et al
    Impact of preoperative 18F-FDG PET/CT on survival of resected mono-metastatic non-small cell lung cancer.
    Lung Cancer. 2016;93:28-34.
    PubMed     Text format     Abstract available


  397. VAN DEN BOOGAART VE, de Lussanet QG, Houben RM, de Ruysscher D, et al
    Inter-reader reproducibility of dynamic contrast-enhanced magnetic resonance imaging in patients with non-small cell lung cancer treated with bevacizumab and erlotinib.
    Lung Cancer. 2016;93:20-7.
    PubMed     Text format     Abstract available


  398. MENIAWY TM, Lake RA, McDonnell AM, Millward MJ, et al
    PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.
    Lung Cancer. 2016;93:9-16.
    PubMed     Text format     Abstract available


  399. LIM SM, Cho BC, Kim SW, Kang SY, et al
    A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
    Lung Cancer. 2016;93:1-8.
    PubMed     Text format     Abstract available


  400. MENGOLI MC, Barbieri F, Bertolini F, Tiseo M, et al
    K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
    Lung Cancer. 2016;93:55-8.
    PubMed     Text format     Abstract available


  401. LI D, Zhang L, Zhou J, Chen H, et al
    Cigarette smoke extract exposure induces EGFR-TKI resistance in EGFR-mutated NSCLC via mediating Src activation and EMT.
    Lung Cancer. 2016;93:35-42.
    PubMed     Text format     Abstract available


  402. VAN GEEL RM, Hendrikx JJ, Vahl JE, van Leerdam ME, et al
    Crizotinib-induced fatal fulminant liver failure.
    Lung Cancer. 2016;93:17-9.
    PubMed     Text format     Abstract available


    February 2016
  403. KATO T, Wada H, Patel P, Hu HP, et al
    Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients.
    Lung Cancer. 2016;92:53-61.
    PubMed     Text format     Abstract available


  404. TSURUGAI Y, Kozuka T, Ishizuka N, Oguchi M, et al
    Relationship between the consolidation to maximum tumor diameter ratio and outcomes following stereotactic body radiotherapy for stage I non-small-cell lung cancer.
    Lung Cancer. 2016;92:47-52.
    PubMed     Text format     Abstract available


  405. KRISHNASWAMY S, Mohammed AK, Amer OE, Tripathi G, et al
    Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.
    Lung Cancer. 2016;92:41-6.
    PubMed     Text format     Abstract available


  406. SMIT E, Moro-Sibilot D, Carpeno Jde C, Lesniewski-Kmak K, et al
    Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study.
    Lung Cancer. 2016;92:35-40.
    PubMed     Text format     Abstract available


  407. HAMES ML, Chen H, Iams W, Aston J, et al
    Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2016;92:29-34.
    PubMed     Text format     Abstract available


  408. GUERRERO E, Ahmed M
    The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer.
    Lung Cancer. 2016;92:22-8.
    PubMed     Text format     Abstract available


  409. MALOTTKI K, Popat S, Deeks JJ, Riley RD, et al
    Problems of variable biomarker evaluation in stratified medicine research-A case study of ERCC1 in non-small-cell lung cancer.
    Lung Cancer. 2016;92:1-7.
    PubMed     Text format     Abstract available


  410. KODITYAL S, Elvin JA, Squillace R, Agarwal N, et al
    A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
    Lung Cancer. 2016;92:19-21.
    PubMed     Text format     Abstract available


  411. CAUMONT C, Veillon R, Gros A, Laharanne E, et al
    Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.
    Lung Cancer. 2016;92:15-8.
    PubMed     Text format     Abstract available


  412. SCHMIDT LH, Kuemmel A, Schliemann C, Schulze A, et al
    Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC.
    Lung Cancer. 2016;92:8-14.
    PubMed     Text format     Abstract available


    January 2016
  413. KINOSHITA T, Fujii H, Hayashi Y, Kamiyama I, et al
    Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
    Lung Cancer. 2016;91:56-66.
    PubMed     Text format     Abstract available


  414. RIEBER J, Deeg A, Ullrich E, Foerster R, et al
    Outcome and prognostic factors of postoperative radiation therapy (PORT) after incomplete resection of non-small cell lung cancer (NSCLC).
    Lung Cancer. 2016;91:41-7.
    PubMed     Text format     Abstract available


  415. SUDA K, Murakami I, Sakai K, Tomizawa K, et al
    Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
    Lung Cancer. 2016;91:36-40.
    PubMed     Text format     Abstract available


  416. FIELD JK, Devaraj A, Duffy SW, Baldwin DR, et al
    CT screening for lung cancer: Is the evidence strong enough?
    Lung Cancer. 2016;91:29-35.
    PubMed     Text format     Abstract available


  417. TISSOT C, Couraud S, Tanguy R, Bringuier PP, et al
    Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
    Lung Cancer. 2016;91:23-8.
    PubMed     Text format     Abstract available


  418. KIM G, An HJ, Lee MJ, Song JY, et al
    Hsa-miR-1246 and hsa-miR-1290 are associated with stemness and invasiveness of non-small cell lung cancer.
    Lung Cancer. 2016;91:15-22.
    PubMed     Text format     Abstract available


  419. DEBIEUVRE D, Oster JP, Riou R, Berruchon J, et al
    The new face of non-small-cell lung cancer in men: Results of two French prospective epidemiological studies conducted 10 years apart.
    Lung Cancer. 2016;91:1-6.
    PubMed     Text format     Abstract available


  420. CALLISTER ME, Baldwin DR
    How should pulmonary nodules be optimally investigated and managed?
    Lung Cancer. 2016;91:48-55.
    PubMed     Text format     Abstract available


  421. SARUWATARI K, Ikemura S, Sekihara K, Kuwata T, et al
    Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.
    Lung Cancer. 2016;91:7-14.
    PubMed     Text format     Abstract available


  422. BAAS P, van Meerbeeck J
    Money rules the world.
    Lung Cancer. 2016;91:77-8.
    PubMed     Text format    


  423. OU SH, Milliken JC, Azada MC, Miller VA, et al
    ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
    Lung Cancer. 2016;91:70-2.
    PubMed     Text format     Abstract available


    December 2015
  424. DAUTZENBERG B, Garelik D
    Patients with lung cancer: Are electronic cigarettes harmful, useful?
    Lung Cancer. 2015 Dec 24. pii: S0169-5002(15)30123.
    PubMed     Text format     Abstract available


  425. MORO-SIBILOT D, Smit E, de Castro Carpeno J, Lesniewski-Kmak K, et al
    Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study.
    Lung Cancer. 2015;90:427-32.
    PubMed     Text format     Abstract available


  426. KUSAGAYA H, Inui N, Karayama M, Fujisawa T, et al
    Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2015;90:410-6.
    PubMed     Text format     Abstract available


  427. SCHMID-BINDERT G, Engel-Riedel W, Reck M, Schuette W, et al
    A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.
    Lung Cancer. 2015;90:397-404.
    PubMed     Text format     Abstract available


  428. RICARDI U, Badellino S, Filippi AR
    Stereotactic body radiotherapy for early stage lung cancer: History and updated role.
    Lung Cancer. 2015;90:388-96.
    PubMed     Text format     Abstract available


  429. LI A, Niu FY, Han JF, Lou NN, et al
    Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2015;90:375-80.
    PubMed     Text format     Abstract available


    November 2015
  430. VERGNE F, Quere G, Andrieu-Key S, Descourt R, et al
    ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
    Lung Cancer. 2015 Nov 10. pii: S0169-5002(15)30106.
    PubMed     Text format     Abstract available


  431. VALLEE A, Audigier-Valette C, Herbreteau G, Merrien J, et al
    Rapid clearance of circulating tumor DNA during treatment with AZD9291 of a lung cancer patient presenting the resistance EGFR T790M mutation.
    Lung Cancer. 2015 Nov 7. pii: S0169-5002(15)30104.
    PubMed     Text format    


    October 2015
  432. HOWELL M, Chiramel J, Flaum N, Lewis A, et al
    Outcomes of octogenarian (>/=80 yo) patients with advanced non-small cell lung cancer (NSCLC): A single institution experience at the Christie Hospital.
    Lung Cancer. 2015 Oct 28. pii: S0169-5002(15)30094.
    PubMed     Text format    


  433. VAN DER LINDEN N, Bongers ML, Coupe VM, Smit EF, et al
    Costs of non-small cell lung cancer in the Netherlands.
    Lung Cancer. 2015 Oct 17. pii: S0169-5002(15)30084.
    PubMed     Text format     Abstract available


  434. YOKOUCHI H, Ishida T, Yamazaki S, Kikuchi H, et al
    Prognostic impact of clinical variables on surgically resected small-cell lung cancer: Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A).
    Lung Cancer. 2015 Oct 14. pii: S0169-5002(15)30079.
    PubMed     Text format     Abstract available


  435. YOSHIDA T, Yoh K, Niho S, Umemura S, et al
    RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
    Lung Cancer. 2015 Oct 9. pii: S0169-5002(15)30069.
    PubMed     Text format     Abstract available


    July 2015
  436. LEE MS, Liu CY, Su L, Christiani DC, et al
    Polymorphisms in ERCC1 and ERCC2/XPD genes and carcinogen DNA adducts in human lung.
    Lung Cancer. 2015;89:8-12.
    PubMed     Text format     Abstract available


  437. DAVEY P, Ennis M, Aviv R
    Prophylactic cranial irradiation (PCI). Still a no-brainer?
    Lung Cancer. 2015;89:4-7.
    PubMed     Text format     Abstract available


  438. CHAUDHURI AA, Tang C, Binkley MS, Jin M, et al
    Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
    Lung Cancer. 2015;89:50-6.
    PubMed     Text format     Abstract available


  439. HSIEH MS, Lee YH, Chen JS, Lee JM, et al
    Mixed mucoepidermoid carcinoma and adenocarcinoma of the lung: Two cases with unusual histologic features.
    Lung Cancer. 2015;89:80-3.
    PubMed     Text format     Abstract available


  440. NAKAMURA S, Fukui T, Kawaguchi K, Fukumoto K, et al
    Does ground glass opacity-dominant feature have a prognostic significance even in clinical T2aN0M0 lung adenocarcinoma?
    Lung Cancer. 2015;89:38-42.
    PubMed     Text format     Abstract available


  441. AL-AMERI A, Malhotra P, Thygesen H, Plant PK, et al
    Risk of malignancy in pulmonary nodules: A validation study of four prediction models.
    Lung Cancer. 2015;89:27-30.
    PubMed     Text format     Abstract available


    May 2015
  442. TSAI TH, Wu SG, Hsieh MS, Yu CJ, et al
    Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Lung Cancer. 2015;88:208-14.
    PubMed     Text format     Abstract available


  443. SORENSEN SF, Carus A, Meldgaard P
    Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC.
    Lung Cancer. 2015;88:167-73.
    PubMed     Text format     Abstract available


  444. MAO K, Liu F, Liu X, Khuri FR, et al
    Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.
    Lung Cancer. 2015;88:131-8.
    PubMed     Text format     Abstract available


  445. WANG P, Lu S, Mao H, Bai Y, et al
    Identification of biomarkers for the detection of early stage lung adenocarcinoma by microarray profiling of long noncoding RNAs.
    Lung Cancer. 2015;88:147-53.
    PubMed     Text format     Abstract available


  446. WU KL, Tsai MJ, Yang CJ, Chang WA, et al
    Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
    Lung Cancer. 2015;88:187-94.
    PubMed     Text format     Abstract available


  447. OU SH, Greenbowe J, Khan ZU, Azada MC, et al
    I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
    Lung Cancer. 2015;88:231-4.
    PubMed     Text format     Abstract available


  448. FUKUHARA T, Maemondo M, Inoue A, Kobayashi K, et al
    Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.
    Lung Cancer. 2015;88:181-6.
    PubMed     Text format     Abstract available


    April 2015
  449. REIS H, Herold T, Ting S, Worm K, et al
    HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
    Lung Cancer. 2015;88:34-41.
    PubMed     Text format     Abstract available


  450. LE X, Desai NV, Majid A, Karp RS, et al
    De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.
    Lung Cancer. 2015;88:70-3.
    PubMed     Text format     Abstract available


  451. RANGACHARI D, Yamaguchi N, VanderLaan PA, Folch E, et al
    Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.
    Lung Cancer. 2015;88:108-11.
    PubMed     Text format     Abstract available


  452. WIECKOWSKI S, Hemmerle T, Prince SS, Schlienger BD, et al
    Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
    Lung Cancer. 2015;88:9-15.
    PubMed     Text format     Abstract available


  453. SELLA T, Botser D, Navon R, Biran H, et al
    Preferences for disclosure of disease related information among thoracic cancer patients.
    Lung Cancer. 2015;88:100-3.
    PubMed     Text format     Abstract available


  454. DE GREVE J, Moran T, Graas MP, Galdermans D, et al
    Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
    Lung Cancer. 2015;88:63-9.
    PubMed     Text format     Abstract available


  455. KIM MY, Koh J, Kim S, Go H, et al
    Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Lung Cancer. 2015;88:24-33.
    PubMed     Text format     Abstract available


  456. GRIFFIOEN GH, Louie AV, de Bree R, Smit EF, et al
    Second primary lung cancers following a diagnosis of primary head and neck cancer.
    Lung Cancer. 2015;88:94-9.
    PubMed     Text format     Abstract available


    March 2015
  457. WILLIAMS M, Liu ZW, Hunter A, Macbeth F, et al
    An updated systematic review of lung chemo-radiotherapy using a new evidence aggregation method.
    Lung Cancer. 2015;87:290-5.
    PubMed     Text format     Abstract available


  458. PELOSI G, Barbareschi M, Cavazza A, Graziano P, et al
    Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal.
    Lung Cancer. 2015;87:226-31.
    PubMed     Text format     Abstract available


  459. JIANG L, He J, Shi X, Shen J, et al
    Prognosis of synchronous and metachronous multiple primary lung cancers: systematic review and meta-analysis.
    Lung Cancer. 2015;87:303-10.
    PubMed     Text format     Abstract available


  460. ROBESOVA B, Bajerova M, Hausnerova J, Skrickova J, et al
    Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC.
    Lung Cancer. 2015;87:318-20.
    PubMed     Text format     Abstract available


  461. TONG KM, Laskin J, Ho C
    Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility.
    Lung Cancer. 2015;87:296-302.
    PubMed     Text format     Abstract available


  462. MEDJBER K, Freidja ML, Grelet S, Lorenzato M, et al
    Role of nicotinic acetylcholine receptors in cell proliferation and tumour invasion in broncho-pulmonary carcinomas.
    Lung Cancer. 2015;87:258-64.
    PubMed     Text format     Abstract available


  463. YANG Y, Yang Y, Zhou X, Song X, et al
    EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
    Lung Cancer. 2015;87:272-7.
    PubMed     Text format     Abstract available


    February 2015
  464. KOCHER F, Hilbe W, Seeber A, Pircher A, et al
    Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.
    Lung Cancer. 2015;87:193-200.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: